噻托溴胺(tiotropiumbromide)是一个新型的用于治疗慢性阻塞性肺疾病(COPD)的吸入型支气管扩张药物,通过与M3受体结合,拮抗乙酰胆碱的作用,缓解支气管平滑肌的痉挛。吸入一次疗效持续24小时以上。几个大样本的临床试验结果表明,该药物对中重度COPD具有良好的疗效,在改善呼吸困难、生活质量、减少住院次数方面要优于沙美特罗,每日吸入一次噻托溴胺对支气管的舒张作用要明显好于每日吸入四次的溴化异丙托品和每日吸入两次的沙美特罗。而且该药物能够改善通气功能和肺容积,用药的耐受性和安全性也比较好。 Tiotropium bromide is a novel inhaled bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD), which ameliorates bronchial smooth muscle spasms by antagonizing the action of acetylcholine by binding to M3 receptors. Inhalation effect lasting more than 24 hours. The clinical trial results of several large samples show that the drug has good curative effect on moderate and severe COPD and is superior to salmeterol in improving dyspnea, quality of life and reducing the number of hospitalization. Once a day, tiotropium inhaled bronchus Should be significantly better than the ipratropium bromide inhaled four times a day and salmeterol inhaled twice daily. And the drug can improve ventilation and lung volume, medication tolerance and safety is better.